The Future of Lung Cancer Care: It’s Here - The 2nd Vanderbilt Lung Cancer Conference 2026S CME

Add to Calendar The Future of Lung Cancer Care: It’s Here - The 2nd Vanderbilt Lung Cancer Conference 2026S CME 5/8/2026 8:30:00 AM 5/8/2026 2:30:00 PM America/Chicago For More Details: https://vumc.cloud-cme.com/course/courseoverview?EID=111400 Description: Lung cancer is the leading cause of cancer death in the United States, with an estimated 240,000 new diagnoses of lung cancer every year resulting in more deaths than breast, prostate and colon cancer combined. Although the number of new cases of lung cancer is declining, the death rate from lung cancer continues to be staggering. Among new diagnoses in the United States, approximately 40% occur in cur... false MM/DD/YYYY


Friday, May 8, 2026, 8:30 AM - 2:30 PM, Nashville, TN


Specialties - Medicine, Pathology, Microbiology and Immunology, Radiation Oncology, Radiology and Radiological Sciences, Thoracic Surgery


AMA PRA Category 1 Credits™ (6.00 hours), Non-Physician Attendance (6.00 hours)


Lung cancer is the leading cause of cancer death in the United States, with an estimated 240,000 new diagnoses of lung cancer every year resulting in more deaths than breast, prostate and colon cancer combined. Although the number of new cases of lung cancer is declining, the death rate from lung cancer continues to be staggering. Among new diagnoses in the United States, approximately 40% occur in current smokers, 40% in former smokers, and 20% in individuals who have never smoked. The poor prognosis of lung cancer is largely driven by the fact that lung cancer is typically diagnosed at a late stage when curative treatment is no longer possible. Despite evidence that lung cancer screening using low dose CT scans is beneficial and can shift the trend from late to early-stage disease at time of diagnosis, less than 20% of the US eligible population is currently being screened for lung cancer. Recent advances in lung cancer research have provided improved understanding and stratification of the different types of lung cancer, and unprecedented advances in the fields of targeted- and immunotherapy have substantially improved life expectancy and quality of life. As diagnostic and management strategies become more complex, a multidisciplinary approach is increasingly needed, requiring improved communication between relevant stakeholders and patients, and efficient processes to expedite treatment. This activity is designed to provide a comprehensive overview of the current state of affairs in lung cancer screening, diagnosis and treatment and to address common from primary care providers, pulmonologists, oncologists and patients.


Objectives
After participating in this educational activity, you should be able to:

  1. Evaluate emerging technologies across disciplines; participants will be able to describe advances in interventional pulmonology, radiology, surgery, medical oncology, and radiation oncology that are shaping the future of lung cancer care.
  2. Integrate patient-centered perspectives; participants will learn to incorporate the lived experience of patients with lung cancer into clinical decision-making, ensuring that novel technologies align with patient values and preferences.
  3. Apply innovations to multidisciplinary care models; participants will be able to discuss how artificial intelligence, robotics, immunotherapy, and precision medicine can be integrated into multidisciplinary practice to improve early detection, treatment, and outcomes.


Vanderbilt University Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vanderbilt University Medical Center designates this live activity for a maximum 6.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.